KAYOTHERA® —
Biotechnology · Cardiometabolic Therapeutics
$11.2Mtotal raised · 4 rounds on record
$10.5Mlatest round · Venture round · Mar 2022 · 4 yr ago
$736kgrants · 2 grants · CORDIS
10+team · employees, estimated range
Overview
ABOUT KAYOTHERA KayoThera specializes in pioneering a novel class of safe oral antagonists that are the first of their kind to target retinoid signaling. Previously considered "undruggable" the retinoid pathway has posed challenges to drug development for nearly three decades.
Funding and backers
Total raised
$11.2M
4 rounds on record
Latest round
$10.5M
Venture round · Mar 2022 · 4 yr ago
Team
11-50
employees, estimated range
Grants
$736k
2 grants · CORDIS
The money's age
Long since its last round
55 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 24, 2023
Won a grant $338k · CORDIS
May 3, 2023
Won a grant $398k · CORDIS
Mar 31, 2023
New executive Kendall Mohler, Executive Officer, Director · SEC Form D
Mar 24, 2022
New executive Ian Howes, Executive Officer · SEC Form D
Mar 11, 2022
Raised a round Venture round $10.5M · SEC Form D
May 29, 2019
Raised a round Venture round $750k · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | May 2023 | $338k | — | CORDIS |
| Grant | May 2023 | $398k | — | CORDIS |
| Venture round | Mar 2022 | $10.5M | — | SEC Form D |
| Venture round | May 2019 | $750k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | KayoThera, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Mark EspositoExecutive Officer, DirectorSEC Form D
Ken MohlerExecutive Officer, DirectorSEC Form D
Ian HowesExecutive OfficerSEC Form D
Suzanne RettenmierExecutive OfficerSEC Form D
Thong LeExecutive Officer, DirectorSEC Form D
Kendall MohlerExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Psylink is a biotechnology company offering a novel solution to psychedelic drug development.
UNLOCKING THE PHOSPHATASE TARGET CLASS: Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space…
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
PROSION Therapeutics is a drug development company that utilises cutting-edge technology to unlock so far undruggable targets and address…
Soricimed Biopharma is a clinical stage drug development company dedicated to novel trageted treatments for cancer.
Oral biologics, solved with intelligent chemistry. Powered by nGen, our discovery platform, we are pioneering a new modality: nCycle based…
People
Mark Esposito
Executive Officer, Director
Ken Mohler
Executive Officer, Director
Ian Howes
Executive Officer
Suzanne Rettenmier
Executive Officer
Thong Le
Executive Officer, Director
Kendall Mohler
Executive Officer, Director
Yibin Kang
Director
George Heinrich
Director
James Golubieski
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Seattle
United States
HQ
10-50 est. staff